Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics (Nasdaq: NMRA) reported Q2 2026 results and a pipeline update. It said NMRA-215 IND submission is planned for Q4 2026 with Phase 1 initiation by year end. NMRA-511 AD agitation data are expected in Q4 2026, and NMRA-898 schizophrenia Phase 1 data in 2H 2026. Cash was $116.8M, funding operations into Q3 2027; Q2 net loss was $43.1M.
How this was made
The 30-second read
Why it matters
The release combines (1) a cash runway update, (2) a leadership transition to a new CEO, and (3) time-stamped development milestones for three pipeline assets, which can reprice probability-weighted outcomes and near-term expectations.
Market read
Traders can map NMRA’s next catalysts to late-2026 (IND/Phase 1 start and multiple readouts) while monitoring funding duration into Q3 2027.
What to watch
Cash runway is into Q3 2027, but the article does not quantify expected burn beyond Q2, nor does it provide trial enrollment status or interim safety signals that could de-risk timelines.
Background
Neumora is a clinical-stage CNS and cardiometabolic biopharma with multiple programs (NMRA-215, NMRA-511, NMRA-898) and leadership changes.
Ticker impact
Neumora reports Q2 cash of $116.8M and updates NMRA-215 IND submission in Q4 2026, plus NMRA-511 and NMRA-898 clinical data timing.
Moderately positive bias into late-2026 milestones, with volatility tied to IND/Phase 1 and readout execution.
The article provides multiple forward-looking, time-stamped development milestones (IND submission, Phase 1 start, and data readouts) and a quantified cash runway into Q3 2027, which are actionable for biotech risk/reward positioning.
Market effects
Adds incremental signal on NLRP3 inhibition and CNS drug development timelines, but no broad sector policy/regulatory change.
Limited, company-specific biotech catalyst likely to affect small-cap biotech sentiment more than regional macro.
Primarily US-listed biotech-specific; global impact is minimal absent partnership, approval, or regulatory action.
Counterpoint
Milestone timing is still forward-looking; without actual clinical data, the market may discount the calendar and focus on burn rate and dilution risk.
Key entities
- companyNeumora Therapeutics, Inc.
Nasdaq-listed clinical-stage biopharmaceutical company reporting Q2 2026 results and pipeline/business updates.
- programNMRA-215
NLRP3 inhibitor targeting obesity and cardiometabolic disease; IND submission expected in Q4 2026 and Phase 1 start by end of 2026.
- programNMRA-511
Vasopressin 1a receptor antagonist for Alzheimer’s disease agitation; MAD expansion cohort data expected in Q4 2026 and Phase 2 initiation by end of 2026.
- programNMRA-898
M4 positive allosteric modulator for schizophrenia; Phase 1 data expected in second half of 2026.
- executiveJoshua Pinto
Appointed CEO and Board member; previously served in roles of increasing responsibility.